Iberdomide Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase Ib/IIa Dose Escalation Study

May 31 - June 4, 2019; Chicago, Illinois
Iberdomide, a novel IMiD, was well tolerated and active in heavily pretreated patients with R/R MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 204 KB
Released: June 7, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Celgene Corporation

Related Content

From Clinical Care Options (CCO), download slides reviewing key CAR T-cell therapy considerations for managed care and specialty pharmacy professionals

person default Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 4, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue